LTZ Therapeutics Receives FDA Clearance to Begin Clinical Evaluation of LTZ-232 for Advanced Metastatic Colorectal Cancer and Other Solid Tumors
LTZ Therapeutics, a clinical-stage biotechnology company focused on developing next-generation cancer immunotherapies, has announced that the U.S. Food and Drug Administration (FDA) has cleared the company’s Investigational New Drug (IND) application for LTZ-232, allowing the therapy to enter clinical testing in patients with advanced metastatic colorectal cancer (mCRC) and other EpCAM-positive solid tumors.
The regulatory milestone represents an important step forward for the company’s growing oncology pipeline and marks the second investigational therapy from LTZ Therapeutics’ proprietary Universal Myeloid Cell Engager (U-MCE™) Platform to enter clinical development. Building on the progress of its first clinical candidate, LTZ-301, the advancement of LTZ-232 expands the company’s focus beyond hematologic cancers into solid tumors, where effective immunotherapy options remain limited for many patients.
According to LTZ Therapeutics, the first-in-human Phase 1 clinical trial is expected to begin during the fourth quarter of 2026.
Expanding a Novel Immunotherapy Platform
The FDA’s clearance of the IND application enables LTZ Therapeutics to initiate clinical evaluation of a new therapeutic strategy designed to harness the body’s innate immune system to fight cancer.
Unlike many currently approved immunotherapies that primarily target T cells, LTZ-232 has been developed using the company’s proprietary Universal Myeloid Cell Engager (U-MCE™) Platform, which is intended to redirect myeloid immune cells toward tumor cells and stimulate anti-cancer immune activity.
Myeloid cells—including macrophages and other innate immune cells—play an essential role in the body’s first line of immune defense. Researchers increasingly recognize their potential as therapeutic targets because they naturally infiltrate many solid tumors where conventional T-cell-based immunotherapies often have limited effectiveness.
By leveraging these immune cells, LTZ Therapeutics hopes to overcome some of the biological barriers that have historically reduced the effectiveness of immunotherapy in difficult-to-treat cancers.
A New Direction for Solid Tumor Immunotherapy
LTZ-232 represents the company’s second clinical-stage investigational therapy and broadens the application of its technology platform beyond blood cancers.
Its first clinical candidate, LTZ-301, is currently undergoing clinical development for hematologic malignancies.
The progression of LTZ-232 demonstrates the company’s broader strategy of applying its myeloid cell engager technology across multiple cancer types with substantial unmet medical need.
Unlike traditional therapies developed for a single disease indication, the U-MCE™ platform has been designed with flexibility to support multiple tumor types sharing common biological characteristics.
This approach could enable future expansion into numerous epithelial cancers expressing the EpCAM protein.
Targeting EpCAM-Positive Tumors
LTZ-232 has been developed specifically for cancers expressing epithelial cell adhesion molecule (EpCAM), a cell surface protein frequently found in many solid tumors.
EpCAM is highly expressed across a variety of epithelial-derived malignancies, including colorectal, gastric, pancreatic, ovarian, and several other cancers.
Because of its widespread expression in tumor cells and relatively limited distribution in healthy tissues, EpCAM has become an attractive target for precision immunotherapy development.
LTZ Therapeutics believes targeting EpCAM-positive tumors through myeloid immune activation may provide a differentiated therapeutic approach capable of treating multiple solid tumor indications using a common biological mechanism.
Initial Focus on Metastatic Colorectal Cancer
Although LTZ-232 may ultimately be evaluated across several tumor types, the company’s initial clinical development strategy prioritizes advanced metastatic colorectal cancer.
The decision is supported by both disease biology and internal preclinical findings demonstrating consistent EpCAM expression among colorectal tumors together with abundant infiltration of myeloid immune cells within the tumor microenvironment.
These biological characteristics make metastatic colorectal cancer an appropriate initial setting for evaluating the therapeutic potential of the company’s U-MCE™ platform.
The Phase 1 study will also retain flexibility to expand into additional EpCAM-positive cancers as clinical data emerge.
Addressing a Significant Unmet Need
Metastatic colorectal cancer remains one of the most challenging malignancies to treat after progression on standard therapies.
Despite advances in chemotherapy, targeted therapies, and selected immunotherapy approaches, many patients eventually experience disease progression with limited remaining treatment options.
Current immune checkpoint inhibitors have demonstrated substantial benefit primarily in colorectal cancers characterized by microsatellite instability-high (MSI-H) or mismatch repair deficiency.
However, the majority of metastatic colorectal cancers are microsatellite stable (MSS), making them far less responsive to existing immunotherapies.
This large patient population continues to represent a major unmet need within oncology.
LTZ Therapeutics believes its novel mechanism of action may help address this therapeutic gap.
Overcoming the Challenge of “Cold” Tumors
One of the greatest obstacles facing cancer immunotherapy is the presence of so-called “immunologically cold” tumors.
Unlike highly inflamed tumors containing abundant activated immune cells, cold tumors possess limited immune infiltration and create suppressive environments that prevent effective anti-tumor immune responses.
Metastatic colorectal cancer frequently exhibits these characteristics, reducing the effectiveness of many currently available immunotherapies.
LTZ-232 was specifically designed to function within these challenging tumor environments by redirecting myeloid immune cells toward cancer cells.
Rather than relying solely upon T-cell activation, the therapy seeks to recruit innate immune mechanisms capable of initiating broader anti-tumor responses.
Researchers believe this strategy could potentially expand the benefits of immunotherapy into cancers that have historically responded poorly to checkpoint inhibitors.
Phase 1 Trial Planned for Late 2026
Following FDA clearance, LTZ Therapeutics plans to initiate a first-in-human Phase 1 clinical study during the fourth quarter of 2026.
The trial will be conducted as an open-label, multicenter study involving patients with advanced metastatic colorectal cancer and additional eligible solid tumors.
The primary objectives of the early-stage study will include evaluating safety, tolerability, dose escalation, pharmacokinetics, pharmacodynamics, and preliminary anti-tumor activity.
As with most first-in-human oncology trials, investigators will seek to identify an appropriate dose while gathering initial evidence regarding biological activity and clinical responses.
Data generated during this study will help guide future Phase 2 development.
Company Leadership Highlights Milestone
Robert Li, Ph.D., founder and Chief Executive Officer of LTZ Therapeutics, described the IND clearance as an important milestone for both the company and its technology platform.
According to Li, advancing LTZ-232 into clinical development demonstrates the broader therapeutic potential of the Universal Myeloid Cell Engager Platform beyond the company’s initial hematologic oncology program.
He emphasized that introducing a second first-in-class myeloid engager into human studies reflects the company’s commitment to developing innovative immunotherapies capable of addressing cancers with substantial unmet clinical need.
Li also expressed enthusiasm about expanding the company’s pipeline while providing new treatment possibilities for patients facing advanced malignancies.
Novel Approach to Immune Activation
Chief Medical Officer William Grossman, M.D., Ph.D., highlighted the scientific rationale supporting LTZ-232’s development.
According to Grossman, advanced metastatic colorectal cancer remains particularly difficult to treat because of its immunologically cold tumor microenvironment.
These biological conditions often prevent effective activation of conventional anti-tumor immune responses, limiting the clinical benefit of many existing immunotherapy agents.
LTZ-232 has been specifically designed to redirect myeloid immune cells toward tumor tissue, promoting immune activation even within suppressive tumor environments.
The company believes this differentiated mechanism could extend the reach of immunotherapy to patient populations that currently derive little benefit from available immune-based treatments.
Broad Potential Beyond Colorectal Cancer
Although colorectal cancer serves as the initial development focus, LTZ Therapeutics views LTZ-232 as a potentially broad therapeutic platform.
Because EpCAM expression occurs across numerous epithelial malignancies, future clinical studies may evaluate the therapy in additional cancers where current treatment options remain inadequate.
The flexible design of the clinical development program allows investigators to explore activity across multiple solid tumor indications as safety and efficacy data accumulate.
If successful, LTZ-232 could become the foundation for a broader portfolio of myeloid-engaging immunotherapies targeting diverse epithelial cancers.
Building a Diversified Clinical Pipeline
The advancement of LTZ-232 also represents continued growth of LTZ Therapeutics’ overall clinical pipeline.
With LTZ-301 already progressing in hematologic malignancies and LTZ-232 entering development for solid tumors, the company is steadily expanding the clinical validation of its proprietary U-MCE™ technology.
This dual-program strategy enables evaluation of the platform across distinct cancer settings while generating broader evidence supporting the therapeutic value of myeloid cell engagement.
As additional clinical data become available, the company expects to further refine its understanding of how innate immune activation may complement or potentially expand current immunotherapy approaches.
FDA clearance of the IND application for LTZ-232 marks a significant milestone in LTZ Therapeutics’ effort to develop innovative immunotherapies capable of treating cancers that remain difficult to address with existing approaches. By targeting EpCAM-positive tumors through activation of myeloid immune cells, the company is pursuing a differentiated strategy aimed at overcoming the limitations of conventional immunotherapies in immunologically cold solid tumors.
The planned Phase 1 trial, expected to begin in the fourth quarter of 2026, will provide the first opportunity to evaluate LTZ-232 in patients with advanced metastatic colorectal cancer and other eligible solid tumors. As the company’s second clinical-stage candidate, LTZ-232 also reinforces the broader potential of the Universal Myeloid Cell Engager Platform and supports LTZ Therapeutics’ long-term goal of expanding immunotherapy options for patients with cancers that currently have limited effective treatment alternatives.
About LTZ-232
LTZ-232 is a first-in-class bispecific antibody designed to activate tumor-associated macrophages (TAMs) to phagocytose and eliminate tumor cells in solid tumors with high EpCAM+ expression. Preclinical studies demonstrated potent pharmacology across in vitro and in vivo models, supported by a favorable safety profile. LTZ-232 transitions the company’s pipeline strategy into solid tumor indications, with an initial primary focus on advanced mCRC.
LTZ’s Scientific Approach
LTZ’s approach focuses on the fusion of reverse translational science, with a deep understanding of TME biology – especially myeloid biology. Macrophages appear to be one of the most prevalent immune cell populations in TME of various hematologic and solid tumors. Therefore, effectively engaging and activating macrophages to kill cancer cells offers significant therapeutic potential for patients. LTZ is developing its own U-MCE Platform to primarily enhance the phagocytic function of monocytes and macrophages of different polarization states to foster anti-tumor immunity and offer potential therapeutic benefit for other non-oncology diseases.
About LTZ
LTZ Therapeutics is a clinical-stage, immunotherapy-focused biotechnology company pursuing the development of novel therapies, with the company’s Universal Myeloid Cell Engager (U-MCETM) Platform, to improve clinical outcomes in patients with oncology and autoimmune diseases. With headquarters in Redwood City, California and operations in Shenzhen, China, LTZ is dedicated to developing myeloid engager immunotherapies for broad disease indications.